26904-64-3

Basic information

• Product Name: OXYSOPHOCARPINE
• Synonyms: N-OXYSOPHOCARPINE;OXYSOPHOCARPINE;Sophocarpine N-oxide;ophocarpidine;Sophocarpidin
• CAS NO: 26904-64-3
• Molecular Formula: C₁₅H₂₂N₂O₂
• Molecular Weight: 262.351
• Product Categories: Miscellaneous Natural Products;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Inhibitors
• Mol File: 26904-64-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 73-76 °C
• Appearance: /
• PKA: 4.92±0.20(Predicted)
• CAS DataBase Reference: OXYSOPHOCARPINE(CAS DataBase Reference)
• NIST Chemistry Reference: OXYSOPHOCARPINE(26904-64-3)
• EPA Substance Registry System: OXYSOPHOCARPINE(26904-64-3)

Safety Data

• Hazardous Substances Data: 26904-64-3(Hazardous Substances Data)

Usage

Description

Oxysophocarpine, a derivative of Sophocarpine (S676825), is an alkaloid extract derived from the plant Siphocampylus verticillatus. It exhibits potent antiviral properties and is known for its anti-nociceptive effects in rodents when administered systemically or intracerebroventricularly.

Uses

Used in Pharmaceutical Industry:
Oxysophocarpine is used as an antiviral agent for its ability to combat various viral infections. Its potent antiviral properties make it a valuable compound in the development of new medications to treat viral diseases.
Used in Pain Management:
Oxysophocarpine is used as an analgesic agent for its anti-nociceptive effects in rodents. This application highlights its potential in the development of new pain management therapies, particularly for conditions that are difficult to treat with existing medications.
Used in Antiviral Research:
Oxysophocarpine is used as a research compound for studying the mechanisms of viral replication and the development of antiviral drugs. Its unique properties and effectiveness against various viruses make it an important tool in the ongoing search for new antiviral therapies.

InChI:InChI=1/C15H22N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h1,7,11-13,15H,2-6,8-10H2

Upstream product

• 6483-15-4 sophocarpine 

Downstream Products

• 519-02-8 (+)-matrine 

Relevant articles and documents

MATRINIC ACID/ MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF

The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/orAIDS.

Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70

Heat-stress cognate 70 (Hsc70is a host protein required for hepatitis B virus (HBVreplication, and oxymatrine (1suppresses Hsc70 expression. Taking Hsc70 as a target against HBV, 22 analogues of 1 defined with substituents at position 1, 13, or 14 were synthesized and evaluated for their activity on Hsc70 mRNA expression. The SAR revealed that (ithe oxygen atom at the 1-position was not essential, (iiincreasing electron density on the ring D reduced the activity, and (iiiintroducing a proper substituent at the 13-and/or 14-position(s), especially electron-withdrawing groups, might enhance the activity. Among the analogues, 6b possessing 13-ethoxyl afforded an increased activity in respect to 1. Importantly, it was active for either wild-type or lamivudine-resistant HBV, as its target is host Hsc70 but not viral enzymes. LD50 of 6b in mice was over 750 mg/kg in oral route. We consider compound 6b promising for further investigation.